Research has shown that using bebtelovimab to treat COVID-19 in an outpatient setting has been associated with lower odds of hospitalization or death, particularly among immunocompromised and older patients.
A retrospective cohort study compared bebtelovimab-treated patients to propensity score-adjusted and matched non-treated control groups. Participants included high-risk outpatients eligible for bebtelovimab treatment under Emergency Use Authorization with a positive SARS-CoV-2 test from March 30 to May 28, 2022. Treated patients received single-dose intravenous treatment with bebtelovimab. The primary outcome was hospitalization or death over 28 days.